Substance use disorders (SUDs) in oncology populations represent a significant yet underrecognized challenge, with prior research suggesting that up to 27 percent of cancer patients meet criteria for ...

LOS ANGELES, CA - February 13, 2026 - PRESSADVANTAGE - Muse Treatment Alcohol & Drug Rehab Los Angeles has released ...

Adial Pharmaceuticals has announced the issuance of patent number 12,226,401, which enhances their genetic-based approach for treating alcohol and opioid use disorders. This new patent focuses on ...

The glucagon-like peptide 1 (GLP-1) receptor agonist semaglutide has made headlines as a US Food and Drug Administration (FDA)–approved treatment for type 2 diabetes (Ozempic) and obesity (Wegovy).

This Journal feature begins with a case vignette highlighting a common clinical problem. Evidence supporting various strategies is then presented, followed by a review of formal guidelines, when they ...

Please provide your email address to receive an email when new articles are posted on . At 12 months, 7.1% of patients with AUD and cirrhosis in the naltrexone group vs. 28.6% in the placebo group had ...

The first published evidence from humans that semaglutide specifically reduces the symptoms of alcohol use disorder (AUD) has been published in The Journal of Clinical Psychiatry and details a recent ...